The roles of various players in the COVID-19 vaccine rollout continue to evolve among government, public companies, and private entities. Employers, pharmaceutical and supply manufacturers, healthcare service providers, educators, advertisers, transportation and logistics providers, and many others are continuously evaluating the potential implications of vaccine distribution for their industries and organizations worldwide. Morgan Lewis breaks down what opportunities, regulatory considerations, and legal obstacles still lie ahead.
Effective from October 11, 2022, Japan will resume no-visa entry for short-term stays. Quarantine restrictions and mandatory COVID-19 testing at the border, along with other restrictions, will be lifted.
California Governor Gavin Newsom signed Assembly Bill 152 into law on September 29, extending California’s 2022 COVID-19 Supplemental Paid Sick Leave law to December 31, 2022. The bill also creates a program that will reimburse qualifying small businesses and nonprofits for costs incurred providing employees with COVID-19 supplemental paid sick leave.
New York City Mayor Eric Adams officially announced that New York City will rescind its private employer vaccine mandate, effective November 1, 2022.
The Japan government further relaxed its border measures on September 7, 2022. While the number of people infected with COVID-19 in Japan still remains high, the government is gradually changing its conservative approach.
As US federal and local governments have declared mpox (previously known as monkeypox) to be a public health emergency, employers attuned to responding to the COVID-19 pandemic may be left wondering what protocols to implement before and after a positive mpox case. For employers in particular, there are several key differences between the COVID-19 pandemic and the 2022 mpox outbreak.
While state and local governments and local health authorities can continue to require individuals and businesses to maintain stricter standards than the CDC’s recently updated guidance, the changes reflect the CDC’s current assessment of COVID-19 risk. Employers should evaluate their current COVID-19 policies and procedures.
With the COVID-19 pandemic, many industries experienced a major shift in how the personnel of key suppliers worked, with “nonessential” personnel in large part working remotely. When this shift to remote work first happened (rather abruptly for many companies), security was a critical consideration, but one that was handled in many instances outside the supplier contract, with both parties focusing on keeping business operations going with must-have data and security safeguards in place.
The COVID-19 pandemic brought multiple temporary changes for ERISA-governed group health and welfare plans. Certain coverage mandates apply for only the duration of the COVID-19 public health emergency (the Public Health Emergency), while certain ERISA deadline relief applies only during the COVID-19 outbreak period (the Outbreak Period). This LawFlash provides an overview of these two similar—but not identical—legal COVID-19 emergency periods, as well as practical guidance for plan sponsors and administrators anticipating the announced end of the special COVID-19 rules.
Partners Sharon Perley Masling and Sage Fattahian, senior attorney Pierce Blue, and associates Daniel Kadish, Kaiser Chowdhry, and Jake Harper drafted an article for Bloomberg Law about steps employers can take in response to the mpox (previously known as monkeypox) outbreak.
Partner Kathleen Sanzo spoke at a recent Food and Drug Law Institute (FDLI) event, discussing how the US Department of Justice’s (DOJ’s) Consumer Protection Branch works with the US Food and Drug Administration (FDA) to investigate civil and criminal matters involving misbranded products.
The US Department of Health and Human Services has renewed the Public Health Emergency (PHE) for another 90 days, now extending through October.
Partner Daryl Landy was quoted by Law360 about new guidance from the US Equal Employment Opportunity Commission (EEOC) around COVID-19 screening protocol. “Instead of being able to say, we're going to have a blanket, national policy, [now] it should be evaluated location by location, and employee by employee,” Daryl said. “It's a lot of work for employers.”
Partner Scott Memmott and associates Jacob Harper and Jonathan York wrote an article for Law360, explaining that although the US Department of Justice's (DOJ’s) COVID-19 fraud enforcement has so far focused on individuals and entities blatantly abusing pandemic assistance funds, health care and life sciences companies should assess their compliance programs as the DOJ will likely turn to larger-dollar activity at the organization level soon.
Associate Jake Harper, Executive Director of the Center for Telehealth and E-Health Law (CTeL) Christa Natoli, and Director of Policy and External Affairs for CTeL Ben Steinhafel recently discussed the current regulatory landscape for telehealth at both the federal and state level on the Healthcare Strategies podcast.
Partners Lesli Ligorner, Vivien Yu, and Tomoko Fuminaga and associate Jonathan Tang wrote an article for HR Asia about immigration-related developments that impact business travel to and from China, Hong Kong, Singapore, and Japan. They discussed a quarantining pilot, visa requirements, and vaccination developments.
Amid the Equal Employment Opportunity Commission’s updated guidance for employers handling religious objections to COVID-19 vaccinations, partner Michael Puma was quoted by HR Magazine on the business impact of managing these accommodations.